|Bid||0.00 x 3100|
|Ask||0.00 x 900|
|Day's Range||59.97 - 59.99|
|52 Week Range||25.41 - 60.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?
Moody's Japan K.K. has downgraded Astellas Pharma Inc.'s issuer rating to A2 from A1. At the same time, Moody's has changed the ratings outlook to negative from rating under review. This action concludes Moody's review for downgrade that was initiated on 6 December 2019, following Astellas' announcement it would acquire the outstanding stock of Audentes Therapeutics, Inc. Astellas has closed the USD 3 billion acquisition, financing it with debt and cash on hand.
Firm's largest buys of the 4th quarter Continue reading...